Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Structurally Related Kappa Opioid Receptor Agonists with Substantial Differential Signaling Bias: Neuroendocrine and Behavioral Effects in C57BL6 Mice
Amelia Dunn, Brian Reed, Catherine Guariglia, et al.
The International Journal of Neuropsychopharmacology (2018) Vol. 21, Iss. 9, pp. 847-857
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
Kendall L. Mores, Benjamin Cummins, Robert J. Cassell, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 101
Current status of opioid addiction treatment and related preclinical research
Mary Jeanne Kreek, Brian Reed, Eduardo R. Butelman
Science Advances (2019) Vol. 5, Iss. 10
Open Access | Times Cited: 91
Strategies for DevelopingκOpioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects
Kelly F. Paton, Diana Vivian Atigari, Sophia Kaska, et al.
Journal of Pharmacology and Experimental Therapeutics (2020) Vol. 375, Iss. 2, pp. 332-348
Open Access | Times Cited: 45
Functional Selectivity and Antinociceptive Effects of a Novel KOPr Agonist
Andrea Bedini, Lorenzo Di Cesare Mannelli, Laura Micheli, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 44
Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors
Jolien De Neve, Thomas Barlow, Dirk Tourwé, et al.
RSC Medicinal Chemistry (2021) Vol. 12, Iss. 6, pp. 828-870
Open Access | Times Cited: 35
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse
Md Imdadul H. Khan, Benjamin J. Sawyer, Nicholas S. Akins, et al.
European Journal of Medicinal Chemistry (2022) Vol. 243, pp. 114785-114785
Open Access | Times Cited: 27
Signaling Properties of Structurally Diverse Kappa Opioid Receptor Ligands: Toward in Vitro Models of in Vivo Responses
Amelia Dunn, Brian Reed, Jose Erazo, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 8, pp. 3590-3600
Closed Access | Times Cited: 41
Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain
Thomas J. Cirino, Shainnel O. Eans, Jéssica Medina, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 36
Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors
Hildegard A. Wulf, Caroline A. Browne, Carlos A. Zarate, et al.
Psychopharmacology (2022) Vol. 239, Iss. 7, pp. 2309-2316
Closed Access | Times Cited: 19
Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain
Kelly F. Paton, Andrew Biggerstaff, Sophia Kaska, et al.
Frontiers in Neuroscience (2020) Vol. 14
Open Access | Times Cited: 30
An updated assessment of the translational promise of G-protein-biased kappa opioid receptor agonists to treat pain and other indications without debilitating adverse effects
Alexander R. French, Richard M. van Rijn
Pharmacological Research (2022) Vol. 177, pp. 106091-106091
Open Access | Times Cited: 18
Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic Pain
Lisa Wilson, Amy R. Alleyne, Shainnel O. Eans, et al.
Molecules (2022) Vol. 27, Iss. 11, pp. 3617-3617
Open Access | Times Cited: 17
Designing Functionally Selective Noncatechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity
Michael L. Martini, Caroline Ray, Xufen Yu, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 9, pp. 4160-4182
Open Access | Times Cited: 27
The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys
Sally L. Huskinson, Donna M. Platt, C. Austin Zamarripa, et al.
Pharmacology Biochemistry and Behavior (2022) Vol. 217, pp. 173394-173394
Open Access | Times Cited: 16
Endogenous Opiates and Behavior: 2018
Richard J. Bodnar
Peptides (2020) Vol. 132, pp. 170348-170348
Closed Access | Times Cited: 21
The kappa-opioid receptor agonist, triazole 1.1, reduces oxycodone self-administration and enhances oxycodone-induced thermal antinociception in male rats
C. Austin Zamarripa, Tanya Pareek, Hayley M. Schrock, et al.
Psychopharmacology (2021) Vol. 238, Iss. 12, pp. 3463-3476
Open Access | Times Cited: 15
Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice
Amelia Dunn, Kyle A. Windisch, Ariel Ben-Ezra, et al.
Psychopharmacology (2020) Vol. 237, Iss. 8, pp. 2405-2418
Closed Access | Times Cited: 15
Kappa opioid receptor modulation of endometriosis pain in mice
Alejandra Escudero-Lara, David Cabañero, Rafael Maldonado
Neuropharmacology (2021) Vol. 195, pp. 108677-108677
Open Access | Times Cited: 13
Pharmacological and metabolic characterization of the novel synthetic opioid brorphine and its detection in routine casework
Katharina Elisabeth Grafinger, Maurice Wilde, Lorina Otte, et al.
Forensic Science International (2021) Vol. 327, pp. 110989-110989
Closed Access | Times Cited: 13
NOP-Targeted Nonpeptide Ligands
Nurulain T. Zaveri, Michael E. Meyer
Handbook of experimental pharmacology (2019), pp. 37-67
Closed Access | Times Cited: 14
Biased Ligands at the Kappa Opioid Receptor: Fine-Tuning Receptor Pharmacology
Tarsis F. Brust
Handbook of experimental pharmacology (2020), pp. 115-135
Closed Access | Times Cited: 14
The Salvinorin Analogue, Ethoxymethyl Ether Salvinorin B, Promotes Remyelination in Preclinical Models of Multiple Sclerosis
Kelly F. Paton, Katharina Robichon, Nikki Templeton, et al.
Frontiers in Neurology (2021) Vol. 12
Open Access | Times Cited: 12
Naltrexone and nalmefene attenuate cocaine place preference in male mice
Kyle A. Windisch, Brian Reed, Mary Jeanne Kreek
Neuropharmacology (2018) Vol. 140, pp. 174-183
Closed Access | Times Cited: 14
Discovery of Potent Kappa Opioid Receptor Agonists Derived from Akuammicine
Madeline Hennessy, Simone M. Creed, Anna M. Gutridge, et al.
(2024)
Open Access | Times Cited: 1
Discovery of Potent Kappa Opioid Receptor Agonists Derived from Akuammicine
Madeline Hennessy, Simone M. Creed, Anna M. Gutridge, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top